Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders

Makhmalzade, Behzad Sharif; Chavoshy, Fateme

doi:10.4103/japtr.japtr_314_17

Cited by 87 publications

(23 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their mechanism of action is not clearly demonstrated but it is known that they can penetrate through stratum corneum and accumulate in hair follicles. Moreover it has been observed skin penetration into deeper skin layers followed by drug delivery in the intercluster region, one of the penetration pathways through the skin [19]. All of the prepared nanomicellar formulations had a good drug efficiency in the range between 79% and 96%.…”

Section: Resultsmentioning

confidence: 99%

“…Delivery of drugs using nanotechnologies, not only can improve drug stability, but also can reduce skin irritation by avoiding direct contact of the drug with the skin′s surface. The nanomicelles have recently attracted a great deal of attention for drug delivery into the skin for the treatment of dermatological diseases [17,18,19] and in the present research surfactant nanomicelles, able to self-assemble above the critical micelle concentration (CMC), have been chosen as the carrier to drive the hybrid 1 into the skin. The in vitro permeation through and penetration into pig ear skin, a widely accepted model for human skin [20], have been evaluated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma

et al. 2019

View full text Add to dashboard Cite

In this work, hybrid compounds 1–4 obtained by conjugation of the non-steroidal anti-inflammatory drug diclofenac, with natural molecules endowed with antioxidant and antiproliferative activity were prepared. The antiproliferative activity of these hybrids was evaluated on immortalized human keratinocyte (HaCaT) cells stimulated with epidermal growth factor (EGF), an actinic keratosis (AK) model, and on human squamous cell carcinoma (SCC) cells (A431). Hybrid 1 presented the best activity in both cell models. Self-assembling surfactant nanomicelles have been chosen as the carrier to drive the hybrid 1 into the skin; the in vitro permeation through and penetration into pig ear skin have been evaluated. Among the nanostructured formulations tested, Nano3Hybrid20 showed a higher tendency of the hybrid 1 to be retained in the skin rather than permeating it, with a desirable topical and non-systemic action. On these bases, hybrid 1 may represent an attractive lead scaffold for the development of new treatments for AK and SCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Topical administration has several advantages for treatment of skin diseases. Transdermal delivery can avoid metabolism of drugs by the liver, reduce side effects, and achieve local effects (43). Topical administration of AST effectively inhibited UVinduced ocular photokeratitis and AD-like skin inflammation (44,45).…”

Section: Discussionmentioning

confidence: 99%

Improved Anti-Inflammatory Effects of Liposomal Astaxanthin on a Phthalic Anhydride-Induced Atopic Dermatitis Model

et al. 2020

View full text Add to dashboard Cite

Previously, we found that astaxanthin (AST) elicited an anti-inflammatory response in an experimental atopic dermatitis (AD) model. However, the use of AST was limited because of low bioavailability and solubility. We hypothesized that liposome formulation of AST could improve this. In this study, we compared the anti-inflammatory and anti-dermatotic effects of liposomal AST (L-AST) and free AST. We evaluated the effect of L-AST on a phthalic anhydride (PA)-induced animal model of AD by analyzing morphological and histopathological changes. We measured the mRNA levels of AD-related cytokines in skin tissue and immunoglobulin E concentrations in the serum. Oxidative stress and transcriptional activities of signal transducer and activator of transcription 3 (STAT3) and nuclear factor (NF)-κB were analyzed via western blotting and enzyme-linked immunosorbent assay. PA-induced dermatitis severity, epidermal thickening, and infiltration of mast cells in skin tissues were ameliorated by L-AST treatment. L-AST suppressed AD-related inflammatory mediators and the inflammation markers, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in PA-induced skin conditions. Oxidative stress and expression of antioxidant proteins, glutathione peroxidase-1 (GPx-1) and heme oxygenase-1 (HO-1), were recovered by L-AST treatment in skin tissues from PA-induced mice. L-AST treatment reduced transcriptional activity of STAT3 and NF-κB in PA-induced skin tissues. Our results indicate that L-AST could be more effective than free AST for AD therapy.

show abstract

“…Polymeric micelles present a unique architecture where the hydrophobic core can incorporate hydrophobic drugs, such as antifungals, which leads to a very significant improvement in their aqueous solubility [ 134 ]. These systems have attracted attention in drug delivery because their critical micelle concentration (CMC) is several 1000-fold lower (<10 mg/L) than classic micelles, this means that ionic surfactants have greater ease in self-assembling in water to form micelles [ 157 ].…”

Section: Nanotechnology and Mycologymentioning

confidence: 99%

Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources

et al. 2020

View full text Add to dashboard Cite

The high incidence of fungal infections has become a worrisome public health issue, having been aggravated by an increase in host predisposition factors. Despite all the drugs available on the market to treat these diseases, their efficiency is questionable, and their side effects cannot be neglected. Bearing that in mind, it is of upmost importance to synthetize new and innovative carriers for these medicines not only to fight emerging fungal infections but also to avert the increase in drug-resistant strains. Although it has revealed to be a difficult job, new nano-based drug delivery systems and even new cellular targets and compounds with antifungal potential are now being investigated. This article will provide a summary of the state-of-the-art strategies that have been studied in order to improve antifungal therapy and reduce adverse effects of conventional drugs. The bidirectional relationship between Mycology and Nanotechnology will be also explained. Furthermore, the article will focus on new compounds from the marine environment which have a proven antifungal potential and may act as platforms to discover drug-like characteristics, highlighting the challenges of the translation of these natural compounds into the clinical pipeline.

show abstract

Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders

Cited by 87 publications

References 51 publications

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma

Improved Anti-Inflammatory Effects of Liposomal Astaxanthin on a Phthalic Anhydride-Induced Atopic Dermatitis Model

Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources

Contact Info

Product

Resources

About